RIGL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RI

Mkt Cap

$858.4M

Volume

110.88K

Next Earnings

November 3rd

Loading chart

RI

RIGLRigel Pharmaceuticals Inc. (New)

RIGL

Pay with—

Available Balance0.00

RI

Mkt Cap

$882.6M

Volume

110.88K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Reasons Why Investors Should Consider Betting on Arvinas StockArvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.Zacks Investment Research · Oct 13, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology CandidateArvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.GlobeNewswire Inc. · Sep 28, 2026

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaKnight Therapeutics announced that it received regulatory approval from Colombia's health authority (INVIMA) for TAVALISSE (fostamatinib disodium hexahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The company plans to launch the drug in Colombia in the first half of 2027, following its May 2026 launch in Mexico and an expected Q4 2026 launch in Brazil.GlobeNewswire Inc. · Sep 1, 2026

Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en ColombieKnight Therapeutics Inc. (TSX: GUD) announced regulatory approval from Colombia's INVIMA for TAVALISSE® (fostamatinib disodium heptahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The approval marks a significant milestone in Knight's Latin American expansion strategy following its 2022 licensing agreement with Rigel Pharmaceuticals. The company plans to launch TAVALISSE in Colombia in H1 2027, following launches in Mexico (May 2026) and Brazil (Q4 2026).GlobeNewswire Inc. · Sep 1, 2026

Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.GlobeNewswire Inc. · Jul 29, 2026

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, PfizerRigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.Benzinga · May 12, 2026

Rigel (RIGL) Q2 Revenue Jumps 176%Rigel Pharmaceuticals exceeded Q2 2025 financial expectations with 176.4% revenue growth, driven by strong product sales and a significant Eli Lilly collaboration, raising full-year revenue guidance to $270-$280 million.The Motley Fool · Aug 6, 2025

Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au MexiqueKnight Therapeutics, a specialty pharmaceutical company, announced that its Mexican subsidiary has obtained regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) whose response to prior treatment was insufficient.GlobeNewswire Inc. · Dec 12, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen PharmaceuticalsThe article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.GlobeNewswire Inc. · Nov 6, 2024

Rigel (RIGL) Upgraded to Buy: Here's What You Should KnowRigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Zacks Investment Research · May 10, 2024

to start trading

RI

RIGLRigel Pharmaceuticals Inc. (New)

RIGL

Pay with—

Available Balance0.00

Your PositionYou don't own any RIGL yet.

Related Tickers

Earnings